Partnerships designed for meaningful healthcare progress.

TMAB's proven theranostic platform presents a compelling end-to-end value chain opportunity spanning the discovery, validation, and manufacturing of novel anticancer agents. By integrating diagnostics and targeted therapeutics within a single platform, TMAB is positioned to accelerate oncology drug development, improve treatment precision, and unlock multiple revenue-generating opportunities across the cancer care continuum.

Through its partnership with TMAB, Taobob is mobilizing investment from African institutions, sovereign and private investment groups, and highly skilled professionals in the African diaspora to participate in the growth of a transformative biotechnology enterprise. This initiative creates a unique opportunity for investors to gain exposure to high-impact oncology innovation while contributing to the development of Africa's biomedical research, manufacturing, and healthcare infrastructure.

We invite strategic investors, institutional partners, philanthropic organizations, and diaspora stakeholders to join us in advancing a scalable platform with the potential to deliver meaningful financial returns alongside measurable improvements in global cancer outcomes. Together, we can accelerate the development of next-generation cancer diagnostics and therapeutics while building sustainable biotechnology capacity across Africa and other emerging markets.

Taobob and BioMark Diagnostics are aligned in their mission to improve cancer outcomes through earlier detection. In low- and middle-income countries (LMICs), where most cancers are diagnosed at advanced stages, affordable and accessible diagnostics represent one of the highest-impact opportunities to reduce mortality while lowering the cost of care.

Through its network of African institutions and diaspora professionals, Taobob will help mobilize the investment, strategic partnerships, and local market engagement needed to accelerate the development and deployment of BioMark Diagnostics' solutions. Together, we aim to create a scalable model that delivers both measurable health impact and long-term value across resource-constrained markets facing a rapidly growing cancer burden.